Jardiance Cost in Indiana 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Indiana in 2026?

The retail cash price for Jardiance in Indiana averages $680 per month in 2026, whether you fill at CVS, Walgreens, Kroger, or an independent pharmacy. That figure applies to both the 10 mg and 25 mg strengths. Discount aggregators like GoodRx may reduce that to roughly $550-$620 at select locations, though savings vary by zip code and fluctuate week to week.

No FDA-approved generic empagliflozin existed as of early 2026 [1]. Boehringer Ingelheim and Eli Lilly hold the patent on the Jardiance brand, and the earliest realistic generic entry date remains contested in ongoing patent litigation. Until a generic clears FDA review, Indiana patients face the same national list price as everyone else.

The EMPA-REG OUTCOME trial published in the New England Journal of Medicine demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74-0.99) in adults with type 2 diabetes and established cardiovascular disease [2]. Cardiovascular death alone fell by 38% relative risk reduction. Those outcomes are why payers, employers, and patients continue to seek access despite the high sticker price.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg cut the composite of cardiovascular death or hospitalization for heart failure by 25% vs. placebo (HR 0.75 to 95% CI 0.65-0.86, P<0.001) in patients with heart failure with reduced ejection fraction [3]. The EMPEROR-Preserved trial (N=5,988) then extended that benefit to heart failure with preserved ejection fraction, a population with very few proven therapies at the time [4].

Given that clinical profile, the FDA has approved Jardiance for three separate indications: type 2 diabetes mellitus (to reduce cardiovascular death), heart failure regardless of ejection fraction, and chronic kidney disease to reduce the risk of kidney function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure [1].

Indiana Medicaid Coverage for Jardiance

Indiana Medicaid covers Jardiance for heart failure and chronic kidney disease but does not list it as a covered benefit for type 2 diabetes as a stand-alone indication. Members diagnosed with HFrEF, HFpEF, or CKD with the appropriate ICD-10 codes may qualify for coverage after prior authorization.

The Indiana Medicaid Preferred Drug List (PDL) updated in 2024 added SGLT2 inhibitors to its covered formulary for cardiovascular and renal indications following the American Diabetes Association Standards of Care recommendation that SGLT2 inhibitors with proven cardiovascular or renal benefit be prioritized in patients with T2D who also have atherosclerotic cardiovascular disease, CKD, or heart failure [5]. The ADA states directly: "For patients with T2D and CKD, an SGLT2 inhibitor with evidence of reducing CKD progression or cardiovascular events is recommended" [5].

Prior authorization requirements for Indiana Medicaid typically include documentation of the qualifying diagnosis, a prescribing provider's clinical notes, and evidence of a creatinine or eGFR measurement within the past 12 months. The CREDENCE trial (N=4,401) and the EMPA-KIDNEY trial (N=6,609) supplied the renal outcome data that drove those PA criteria [6][7]. EMPA-KIDNEY showed a 28% relative reduction in the risk of progression of kidney disease or cardiovascular death (HR 0.72 to 95% CI 0.64-0.82, P<0.001) [7].

Indiana Medicaid members denied coverage for a T2D-only indication should ask their provider about appealing with documentation of any concurrent ASCVD, heart failure, or CKD, because even a secondary diagnosis of those conditions may shift the coverage determination.

Commercial Insurance Coverage of Jardiance in Indiana

Most commercial plans sold in Indiana cover Jardiance on Tier 3 or Tier 4, which translates to copays between $60 and $200 per month depending on the plan design. A smaller number of employer-sponsored plans that have adopted value-based formularies place Jardiance on Tier 2, cutting copays to the $30-$60 range.

The Boehringer Ingelheim / Lilly savings card (discussed in detail below) is available only to commercially insured patients, not to those on Medicaid, Medicare, or any federal health program. Indiana residents enrolled in Marketplace plans purchased through healthcare.gov are generally eligible for the savings card if their plan covers Jardiance at any tier.

Plans that do not cover Jardiance at all are less common than they were before 2021, largely because the DAPA-HF and EMPEROR trials created coverage mandates in many states. Indiana has not enacted a specific SGLT2 mandate as of 2026, but the national trend toward cardiorenal benefit coverage has shifted most major Indiana carriers, including Anthem Blue Cross Blue Shield Indiana, Cigna Indiana, and UnitedHealthcare Indiana, toward some level of formulary inclusion.

Checking your specific formulary matters more than checking the carrier name. The same insurer can operate dozens of distinct formulary tiers across different group contracts. Call the member services number on your insurance card and ask for the formulary tier and step-therapy requirements for NDC 0597-0149-37 (Jardiance 10 mg) or NDC 0597-0148-37 (Jardiance 25 mg) before assuming coverage applies.

The Boehringer Ingelheim and Lilly Jardiance Savings Card

Boehringer Ingelheim and Eli Lilly jointly market a savings card program that allows eligible commercially insured Indiana patients to pay as little as $10 per 30-day fill, with a maximum savings of $150 per month. Patients without insurance may also use the card and pay a negotiated cash price, though the discount is smaller and capped differently.

Eligibility rules for 2026 require that the patient be a U.S. resident, not enrolled in Medicare Part D, Medicaid, or any government-funded program, and that the prescription be for an FDA-approved indication. The card is applied at the pharmacy point of sale and does not require any income verification.

To activate: visit the official Jardiance savings page at jardiance.com, register with your name, date of birth, and zip code, and download or print the card. Many Indiana pharmacies can also look up the card electronically if you provide your registration number. The savings card applies to one prescription per fill, and the annual maximum savings are capped, so patients filling 12 months of prescriptions at $10 copay may hit the annual limit mid-year and face the full tier cost for the remainder of the benefit year.

Patients who reach that annual cap should contact Boehringer Ingelheim's patient assistance line (1-800-556-8317) to ask about the separate Jardiance patient assistance program, which provides free medication to uninsured or underinsured patients who meet income thresholds (typically at or below 400% of the federal poverty level).

Compounded Empagliflozin in Indiana: Legality and Cost

Compounded empagliflozin prepared by a state-licensed 503A compounding pharmacy is legal in Indiana as of 2026. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. These pharmacies are regulated by the Indiana Board of Pharmacy and must follow USP standards for non-sterile compounding.

The key legal distinction is between 503A (patient-specific compounding, licensed at the state level) and 503B (outsourcing facilities, regulated at the federal level by FDA). Indiana has functioning 503A pharmacies that compound empagliflozin capsules or oral suspensions. 503B compounding of empagliflozin is more restricted because Jardiance is not on the FDA's drug shortage list, and the FDA has signaled scrutiny toward compounded copies of non-shortage brand drugs [8].

The cost of compounded empagliflozin in Indiana varies widely by pharmacy and formulation. Some 503A pharmacies offer 90-day supplies at costs meaningfully below the brand price; others price similarly. Patients should request a written cost estimate before transferring a prescription. Quality verification matters: ask the compounding pharmacy for a certificate of analysis (CoA) showing that the active pharmaceutical ingredient (API) was tested for identity, potency, and purity before compounding. A CoA from an ISO-accredited third-party laboratory is the minimum standard.

The FDA's guidance on compounding distinguishes between pharmacies that use FDA-registered API suppliers and those that do not [8]. Reputable Indiana 503A pharmacies source empagliflozin API from FDA-registered suppliers and can provide documentation on request. If a pharmacy cannot produce that documentation, patients should find a different provider.

Clinically, compounded empagliflozin has not been tested in the same large randomized trials as the Jardiance brand. EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY all used the branded formulation [2][3][4][7]. Bioequivalence data for compounded preparations are not publicly available. That does not mean compounded empagliflozin is ineffective, but it does mean that patients and prescribers are extrapolating from brand-name trial data.

Telehealth Prescribing of Jardiance in Indiana

Telehealth prescribing of Jardiance is legal in Indiana for established patient-provider relationships. Indiana follows federal telehealth prescribing rules for controlled substances but allows non-controlled prescriptions (Jardiance is not a controlled substance) to be issued after a synchronous audio-video visit [9].

Indiana's telehealth statute (IC 25-1-9.5) permits any licensed Indiana prescriber to issue a Jardiance prescription following a telehealth encounter that meets the standard of care for an in-person visit. The prescriber must document a clinical evaluation sufficient to diagnose the qualifying condition (T2D, heart failure, or CKD), review relevant labs (HbA1c, eGFR, urine albumin-to-creatinine ratio), and assess contraindications including recurrent urinary tract infections, genital mycotic infections, and eGFR below 20 mL/min/1.73 m2 [1].

The FDA label for Jardiance notes that empagliflozin is not recommended when eGFR is <20 mL/min/1.73 m2 for the glycemic indication, though the cardiovascular and renal indications may still apply at lower eGFR thresholds [1]. A telehealth provider who does not review a current eGFR before prescribing is not meeting the standard of care. Ask any telehealth platform whether they require current lab work before issuing the prescription.

HealthRX telehealth visits in Indiana include a laboratory review step. Prescribers do not issue empagliflozin prescriptions without a creatinine-based eGFR drawn within the past 90 days.

How to Get the Cheapest Jardiance in Indiana: A Step-by-Step Approach

Paying less for Jardiance in Indiana requires working through a defined sequence rather than relying on a single discount source.

Step 1: Confirm your insurance formulary tier. Call your plan's member services line and ask for the tier placement and any step-therapy requirements for empagliflozin (brand name: Jardiance). If it sits on Tier 3 or 4, ask whether a formulary exception is available given documented cardiovascular or renal comorbidities.

Step 2: Apply the Boehringer Ingelheim / Lilly savings card. If you have commercial insurance, register at jardiance.com and apply the card at your Indiana pharmacy. The $10 monthly copay option applies while you remain below the annual savings cap.

Step 3: Compare GoodRx and similar aggregators. GoodRx, RxSaver, and NeedyMeds list Indiana pharmacy prices for Jardiance. Prices differ meaningfully between pharmacies even within the same city. A Carmel, Indiana CVS may price differently from a Fishers Kroger on the same day.

Step 4: Ask your prescriber about the 10 mg dose. The 10 mg and 25 mg strengths cost the same at retail. For cardiovascular and renal indications, the 10 mg dose used in EMPA-REG OUTCOME and EMPA-KIDNEY produced the primary outcomes [2][7]. Starting at 10 mg and remaining there is clinically appropriate for most patients and saves nothing financially, but it avoids any argument for dose escalation that might complicate prior authorization renewals.

Step 5: Explore compounded empagliflozin. If you lack insurance coverage, have exceeded the savings card cap, or are uninsured, ask your HealthRX provider about a prescription to a licensed Indiana 503A compounding pharmacy. Request the CoA before filling.

Step 6: Apply for the patient assistance program. Boehringer Ingelheim's Together in Health patient assistance program provides Jardiance at no cost to qualifying uninsured or underinsured patients. Income documentation is required. Applications are processed in approximately 2-4 weeks.

Side Effects and Contraindications Indiana Patients Should Know

Empagliflozin carries a class-wide FDA warning for Fournier's gangrene (necrotizing fasciitis of the perineum), a rare but severe infection reported with SGLT2 inhibitors [1]. Patients should seek immediate care for any perineal pain, tenderness, erythema, or swelling.

Genital mycotic infections occur in approximately 6% of women and 3% of men taking empagliflozin [1]. Urinary tract infections are modestly more frequent. Both are manageable with standard antifungal or antibiotic therapy and rarely require discontinuation.

Diabetic ketoacidosis has been reported with SGLT2 inhibitors even when blood glucose is not dramatically elevated. The FDA label advises assessing patients who present with metabolic acidosis for DKA regardless of glucose level [1]. Indiana prescribers should counsel patients to hold empagliflozin 3 days before planned major surgery or prolonged fasting.

Volume depletion and hypotension may occur, particularly in elderly patients or those taking loop diuretics concurrently. The EMPEROR-Reduced trial population had a median age of 67 years and 19% were over 75, providing reassurance that the drug is manageable in older adults when monitored appropriately [3].

What Labs Does My Indiana Provider Need Before Prescribing Jardiance?

Before issuing an empagliflozin prescription, a clinically complete evaluation includes serum creatinine with calculated eGFR, urine albumin-to-creatinine ratio (UACR), HbA1c (for T2D indication), a basic metabolic panel to assess baseline electrolytes, and a current medication list to screen for concurrent diuretics or nephrotoxic agents.

The CREDENCE trial (N=4,401, mean baseline eGFR 56.2 mL/min/1.73 m2) used canagliflozin rather than empagliflozin but established the renal-protection framework that now informs prescribing across the SGLT2 class [6]. EMPA-KIDNEY enrolled patients with eGFR as low as 20 mL/min/1.73 m2 and showed meaningful benefit at that threshold [7]. Those trial populations define the realistic eGFR range within which empagliflozin is prescribed in 2026.

The American Heart Association's 2022 guideline on management of heart failure gives SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with HFrEF regardless of diabetes status [10]. That guideline language reads: "In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality" [10]. That recommendation level is the same given to beta-blockers and ACE inhibitors in HFrEF, a meaningful signal about how the medical community views the evidence.